CALML4

Across TCGA pan-cancer cohorts, CALML4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CALML4 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CALML4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CALML4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CALML4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.667	0.387	<.001	86	view →
LSCC	OS	Quartile	All	0.937	0.366	<.001	37	view →
CCRCC	OS	Quartile	II,III,IV	0.985	0.104	.024	14	view →
LUAD	DFS	Quartile	All	0.881	0.457	.004	4	view →
GBM	OS	Median	All	0.478	0.932	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CALML4–PDAC (OS)

Open the PDAC breakdown →